NCT07881458 · Eli Lilly and Company
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
(AMPLIFY-2)
What this study is about
The purpose of this study is to investigate the effectiveness and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.
View original scientific description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.
Interventions
DRUG
eloralintide and tirzepatide
Administered SC
DRUG
Tirzepatide
Administered SC
Primary outcome measures
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 100
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Have type 2 diabetes
- Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
- Have a BMI of ≥27 kg/m2 at screening
- Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
Exclusion criteria
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- Have taken any of the following within 90 days prior to screening
- medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
- dipeptidyl peptidase 4 (DPP-4) inhibitors, and
- Have had within 90 days prior to screening:
- heart attack
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Where
- Tucson, Arizona
- Los Alamitos, California
- Los Angeles, California
- Aurora, Colorado
- Pembroke Pines, Florida
- Weston, Florida
- Dalton, Georgia
- Honolulu, Hawaii
- Indianapolis, Indiana
- Eunice, Louisiana
- Marrero, Louisiana
- St Louis, Missouri
And 11 more locations — see the full list below.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 4, 2026 · Source of record for eligibility and locations